Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**S05179** is a Servier-developed, oral fixed-dose quadruple single-pill combination for uncontrolled essential hypertension. It contains perindopril, indapamide, amlodipine, and bisoprolol at doses of 10 mg/2.5 mg/5 mg/5 mg or 10 mg/2.5 mg/10 mg/5 mg. The combination provides complementary antihypertensive mechanisms: angiotensin-converting enzyme inhibition by perindopril, natriuresis and diuresis by indapamide, L-type calcium-channel blockade by amlodipine, and selective beta-1 adrenergic receptor blockade by bisoprolol. In the Phase 3 QUADRO trial, S05179 was evaluated against free perindopril, indapamide, and amlodipine triple therapy in patients whose blood pressure remained uncontrolled on triple therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S05179.